
Abstract Objectives Asthma is a chronic inflammatory airway disease involving immune dysregulation and epithelial barrier impairment. Dongwan Zhike granules (DW), a multicomponent botanical formulation, exhibits potential anti-inflammatory effects, but its pharmacological mechanisms remain unclear. This study investigated the therapeutic effects and mechanisms of DW in allergic airway inflammation. Methods The chemical composition of DW was characterized using a ultra-high-performance liquid chromatography coupled with Q Exactive mass spectrometry (UHPLC–Q Exactive MS). An ovalbumin (OVA)-induced mouse model was established to evaluate airway inflammation. Integrated lung transcriptomics, gut microbiota sequencing, serum metabolomics, and an IL-17A-stimulated airway organoid model were applied to elucidate the underlying mechanisms. Key findings DW alleviated OVA-induced airway pathological injury and inflammatory cell infiltration. Transcriptomic analysis revealed that DW suppressed interleukin-17 (IL-17) signaling-related genes, including Cxcl1, Cxcl2, Mmp13, S100a8, and S100a9. Multiomics analysis revealed that DW treatment was associated with gut microbial remodeling and alterations in eicosapentaenoic acid (EPA)-related lipid metabolism. In airway organoids, DW and EPA reduced IL-1β, IL-6, and TNF-α production and preserved ZO-1 expression, supporting EPA as a candidate metabolic mediator associated with the effects of DW. Conclusions DW attenuates airway inflammation through modulation of IL-17-associated inflammatory responses, accompanied by alterations in gut microbial composition and EPA-related lipid metabolism. These findings provide preclinical evidence supporting further investigation of DW in allergic airway inflammation.
Abstract Objectives Scoparone (SCO) has demonstrated hepatoprotective potential in previous studies, whereas its molecular mechanisms against alcohol-associated liver disease (ALD) remain unclear. This study investigated the protective effects and underlying mechanisms of SCO in ethanol-induced HepG2 cells. Methods Network pharmacology and molecular docking were employed to predict the potential targets and signaling pathways of SCO against ALD. Ethanol-induced HepG2 cells were used to validate the predicted mechanisms by biochemical assays, flow cytometry, immunofluorescence staining, quantitative real-time polymerase chain reaction and western blotting. Key findings Network pharmacology identified 109 overlapping targets between SCO and ALD, with the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway emerging as a key pathway. SCO enhanced alcohol metabolism, attenuated oxidative stress, restored mitochondrial membrane potential, and suppressed ethanol-induced apoptosis. Mechanistically, SCO activated PI3K/Akt signaling, thereby enhancing nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) antioxidant signaling and suppressing the phosphorylated forkhead box O1 (FoxO1)/FoxO1-associated apoptotic signaling. These protective effects were markedly reversed by the PI3K inhibitor LY294002. Conclusions SCO protects against ethanol-induced hepatocyte injury by activating the PI3K/Akt signaling pathway, thereby enhancing Nrf2/HO-1-mediated antioxidant defense and suppressing FoxO1-associated apoptotic signaling. These findings provide preliminary mechanistic evidence supporting further preclinical investigation of SCO in alcohol-associated liver injury.
Abstract Objectives Crohn’s disease is a chronic inflammatory bowel disease associated with gut microbiota imbalance and immune dysregulation. This study aimed to identify candidate key protein targets of Crohn’s disease and explore candidate therapeutic compounds derived from gut microbiota metabolites and medicinal plants. Methods Gene expression data from Crohn’s disease patients were obtained from public databases. Hub targets of gut microbiota metabolites were retrieved from the gutMGene database, and NOD2-related genes were obtained from GeneCards. Differentially expressed genes were identified using machine learning combined with feature attribution analysis. Subcellular localization and external datasets were used for validation. Drug-likeness and toxicity of microbial metabolites were assessed, and active compounds from medicinal plants were predicted via database mining and validated by molecular docking. Key findings Interleukin-1 beta and matrix metalloproteinase-1 were identified as key genes. Seven gut microbiota-derived metabolites showed favourable drug-likeness without predicted carcinogenicity or hepatotoxicity. Several compounds from Panax ginseng and Scutellaria baicalensis exhibited strong binding affinity to the target proteins. Conclusions Interleukin-1 beta and matrix metalloproteinase-1 are candidate key proteins in Crohn’s disease and are associated with the NOD2-related downstream inflammatory network, including nuclear factor kappa-B signalling. Gut microbiota metabolites may influence this network and represent candidate molecules for further investigation.
Abstract Objectives Voltage-gated sodium channel subtype 1.7 (Nav1.7) is a promising target for cancer-induced bone pain (CIBP), but existing inhibitors show limited clinical efficacy. We previously demonstrated that Compound Kushen Injection (CKI) alleviates CIBP in female rats by inhibiting Nav1.7 expression, but its bioactive constituents remained unclear. This study aimed to identify the active constituent in CKI responsible for Nav1.7 inhibition and to elucidate its mechanism of analgesic action in CIBP. Methods CKI constituents were systematically screened for inhibitory activity against Nav1.7 expression, and the analgesic efficacy of sophocarpine (SC) was evaluated in a female rat model of CIBP. Western blot, immunofluorescence, and quantitative real-time PCR were used to investigate the mechanisms of SC in the alleviation of CIBP. Key findings SC was identified as a potent Nav1.7 expression inhibitor, with an IC50 of 0.002 μg/ml, much lower than that of PF-05089771 (IC50 = 0.120 μg/ml). In vivo, SC alleviated nociceptive hypersensitivity and spontaneous pain in female CIBP rats. Furthermore, SC suppressed Nav1.7 expression in spinal cord and dorsal root ganglia, and also downregulated nerve growth factor, tropomyosin receptor kinase A, and serum and glucocorticoid-regulated kinase 1, while inhibiting phosphorylation of neural precursor cell expressed developmentally down-regulated 4-2 and extracellular signal-regulated kinase 1/2. Conclusions This study identifies SC as an inhibitor of Nav1.7 expression, providing a promising lead compound for CIBP treatment.
Abstract Objectives To synthesize current knowledge of the taxonomy, ethnopharmacology, phytochemistry, and pharmacological potential of Anemone sensu lato, including lineages historically treated as Pulsatilla and Hepatica, and assess its relevance to natural-product and drug-discovery research. Methods Literature in Scopus, Web of Science Core Collection, PubMed, and Google Scholar was reviewed through March 2026. Scientific names and synonymy were verified using the International Plant Names Index and World Flora Online. Key findings Anemone taxa are traditionally used for inflammatory, infectious, painful, and wound-related conditions and contain abundant triterpenoid saponins, alongside flavonoids, phenolic acids, lactone derivatives, and minor metabolites. Triterpenoid saponins are the predominant bioactive class and are associated with antibacterial, antioxidant, anti-inflammatory, anticancer, hepatoprotective, antidiabetic, and tissue-protective effects in preclinical models. Reported mechanisms involve oxidative stress, inflammatory mediators, apoptosis-related pathways, and proliferative signaling. Translation remains limited by taxonomic ambiguity, interspecific chemical variability, insufficient extract standardization, incomplete pharmacokinetic characterization, and inadequate toxicity assessment. Conclusions Anemone taxa are promising sources of pharmacologically relevant natural products. Rigorous species authentication, standardized phytochemical profiling, harmonized safety evaluation, and clinically relevant models are required before therapeutic development can be advanced.